Skip to content

High-Definition Transcranial Direct Current Stimulation (HD-tDCS) for Sensory Deficits in Complex Traumatic Brain Injury

High-Definition Transcranial Direct Current Stimulation (HD-tDCS) for Sensory Deficits in Complex Traumatic Brain Injury

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03799458
Acronym
NAVIGATE-TBI
Enrollment
79
Registered
2019-01-10
Start date
2018-07-11
Completion date
2023-11-15
Last updated
2025-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Traumatic Brain Injury

Brief summary

Aim 1: To use magnetoencephalography (MEG) and magnetic resonance imaging (MRI) in Veterans and civilians with mild traumatic brain injury (mTBI) and sensory postconcussive symptoms (PCS) to demonstrate the mechanism of therapeutic benefit of HD-tDCS for sensory symptoms, as shown by reliable changes in the activity of the cognitive control network (CCN) and sensory system network (SSN) following stimulation; Aim 2: this intervention will result in long-term improvements in measures of executive function, depression/anxiety, and quality of life.

Detailed description

Experimental Design and Methods Participants: 120 subjects will be recruited for this study from the NM VA Health Care System and community, 40 healthy controls subjects for an imaging-only group, and 80 mTBI subjects for the stimulation arm who have suffered injury at least 3 months prior to study enrollment, but not more than 15 years prior to enrollment. All participants will be 18-59 years of age. Recruitment: Human participants (ages 18-59) will be invited to come to the University of New Mexico (UNM) to ask questions prior to providing consent. They will be provided with consent forms that describe the study procedures and potential risks. Once informed consent is obtained and the appropriate forms signed, the participant will be assigned a unique research subject identifier (URSI) number, and from that point forward all research data will only be labeled with the URSI number. The key linking identifiers of participants to the URSI will be maintained on a separate database that will be stored behind locked doors, in a locked filing cabinet in a secure area. All participants may then undergo demographic data collection, neuropsychological assessments sensory evaluation, at UNM. They may also undergo MEG and MRI at the Mind Research Network (MRN), located in the same building. Demographic Data: As part of the initial assessment, basic demographic data regarding the subject may be noted down, including age, gender, socioeconomic status, educational attainment, handedness, use of common stimulants such as caffeine, and brain injury severity. They may also be asked if they are willing to allow their medical record to be accessed, for the purposes of confirming details about any traumatic brain injury (TBI) as well as obtaining results of neuroimaging studies done at the time of injury or afterward. This will include medical, surgical, neurological and psychiatric history, results of lab tests, brain scans, electroencephalography tests, medication lists, information from doctor's visits and hospital visits. Neuropsychological testing procedures: All neuropsychological testing will be administered in the Center for Brain Recovery and Repair Core by trained study personnel under direct supervision of core directors. The following domains and tests will be administered: Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research (Examiner); Digit Span; Delis-Kaplan Executive Function Systems (DKEFS) Trail-making Test Conditions 2 and 4; Hopkins Verbal Learning Test (HVLT); Frontal Systems Behavior Scale (FrSBe); Test of Memory Malingering (TOMM); Wechsler Test of Adult Reading (WTAR); Digit Symbol Coding; Handedness; Socioeconomic Status (SES); Patient's Global Impression of Change (PGIC); Glasgow Outcome Scale-Extended (GOSE). Sensory Assessment: Hearing, balance, and vision will be assessed using Common Data Element (CDE) instruments, including the Hearing Handicap Assessment, the Test for Visual Discomfort, the modified Balance Error Scoring System. Oculomotor control will be assessed using virtual reality goggles (Oculus) with implanted eye trackers (iScan). Magnetoencephalography: Magnetoencephalography (MEG) may be done after neuropsychological testing. The participant will sit in the MEG scanner to record brain magnetic fields. MEG setup takes between 10 and 30 minutes, and subsequent recording takes one hour. During MEG assessments participants will complete numerous tasks. Each task is designed to parse different cognitive mechanisms that contribute to sensory performance. In perceptual tasks, participants will discriminate tone pitches amongst novel distracting tones (Auditory Orienting Task; AOT). For eye movement tasks, participants are asked look either towards or away from a visual stimulus (Pro- and Anti-saccades). Magnetic resonance imaging (MRI): MRI scan(s) will be obtained for integration with MEG, as needed for analyses. Total scan time, including participant setup and removal, is expected to take 1 hour. Participants may lie down on a table and be placed into a long donut-shaped magnet. During the scan, participants will be asked to rest quietly or to fixate on a dot on a screen in front of them, or to perform a memory task. No contrast will be used. Any female over 18 who thinks she may be pregnant will complete a urine pregnancy screen before the MRI scan. Following initial testing, the participants in the stimulation arm of the study will receive 10 consecutive weekday sessions of high-definition transcranial direct current stimulation. 2 milliamperes active or sham anodal current will be delivered to the left dorsolateral prefrontal cortex for 30 minutes. During this time, participants will perform vision therapy tasks through a virtual reality headset, or a computer-based working memory task. Skin sensations will be assessed every 10 minutes. Post stimulation testing: the next available weekday following completion of the study protocol, subjects will return to UNM to repeat the demographic, neuropsychological, sensory, and imaging assessments. Long term followup: At 1 month, 3 months and 6 months after stimulation, subjects will be contacted via telephone or meet in person, and will be administered the Beck Depression Inventory (BDI-II), Posttraumatic Stress Disorder Checklist-Military (PCL-M), the Neurobehavioral Symptom Inventory (NSI), and Patient Global Impression of Change (PGIC) quality of life assessment tools utilized before and immediately after, after stimulation. Veterans will undergo these study followup visits at NMVAHCS, and civilians at UNM.

Interventions

Active HD-tDCS delivers active current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates.

Sham HD-tDCS delivers sham current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates

Sponsors

Biomedical Research Institute of New Mexico
CollaboratorOTHER
New Jersey Institute of Technology
CollaboratorOTHER
University of Miami
CollaboratorOTHER
The Mind Research Network
CollaboratorOTHER
The City College of New York
CollaboratorOTHER
University of New Mexico
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Masking description

Active and sham HD-tDCS will be delivered with the same device, and participants and research technician are blinded to the condition.

Intervention model description

120 subjects will be recruited for this study: 40 healthy controls subjects for the imaging-only group, and 80 mTBI subjects for the stimulation arm who have suffered mild TBI at least 3 months prior to study enrollment, but not more than 15 years prior to enrollment. The 80 mTBI subjects will be randomized to either active stimulation (40) or sham stimulation (40).

Eligibility

Sex/Gender
ALL
Age
18 Years to 59 Years
Healthy volunteers
Yes

Inclusion criteria

1. are US Veteran or Active Duty Military personnel aged 18-59, 2. have suffered a mild TBI (alteration in neurological functioning \< 24 hours, loss of consciousness (LOC) less than 30 minutes, Glasgow coma scale (GCS) score (if available) of between 13 and 15 acutely, and less than 24 hours of post-traumatic amnesia (PTA)); 3. were injured between 3 months and 15 years ago; 4. have post-traumatic sensory symptoms as evidenced by endorsing at least 2 out of 12 sensory symptoms on the Neurobehavioral Symptom Inventory (NSI), a measure of post-traumatic symptoms from the NIH Common Data Elements (CDE) to a severity of 3 or higher, 5. are fluent in English, 6. have been on stable doses of any psychotropic medications for the past 2 months. 7. The imaging-only group will have the same inclusion and

Exclusion criteria

except they will not have had a head injury.

Design outcomes

Primary

MeasureTime frameDescription
Postconcussive Sensory Symptoms2 week visitThe NSI is a validated scale of postconcussive symptoms; the Somatic Subscale score captures severity of physical symptoms such as tinnitus, blurry vision, loss of balance, and insomnia. (range 0-48; 0-12 mild; 13-24 moderate; 25-36 severe; 37-48 very severe)

Secondary

MeasureTime frameDescription
Magnetoencephalography Peak Activation2 week visitPeak activation during the Auditory Orienting Task (AOT) performed during magnetoencephalography

Countries

United States

Participant flow

Participants by arm

ArmCount
Active Stimulation TBI Group
Subjects have experienced a mild TBI with ongoing symptoms. Active HD-tDCS will be delivered while subjects perform sensory training tasks. Active HD-tDCS delivers active current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates. Sham delivers a negligible amount of current that does not cause physiological changes.
11
Sham Stimulation TBI Group
Subjects have experienced a mild TBI with ongoing symptoms. Sham HD-tDCS will be delivered while subjects perform sensory training tasks. Active HD-tDCS delivers active current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates. Sham delivers a negligible amount of current that does not cause physiological changes.
10
Imaging Only Control Group
Subjects will undergo initial testing only as a healthy control group.
28
Total49

Baseline characteristics

CharacteristicActive Stimulation TBI GroupSham Stimulation TBI GroupImaging Only Control GroupTotal
Age, Continuous47.3 years
STANDARD_DEVIATION 10.1
49.7 years
STANDARD_DEVIATION 10.5
51.4 years
STANDARD_DEVIATION 13.2
49.2 years
STANDARD_DEVIATION 11.8
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants5 Participants10 Participants18 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
8 Participants5 Participants18 Participants31 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Neurobehavioral Symptom Inventory Somatic Subscale Score19.9 units on a scale
STANDARD_DEVIATION 10.5
18.9 units on a scale
STANDARD_DEVIATION 11.3
2.9 units on a scale
STANDARD_DEVIATION 3.3
10.0 units on a scale
STANDARD_DEVIATION 7.4
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants1 Participants2 Participants4 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants2 Participants2 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants1 Participants1 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants1 Participants1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants2 Participants4 Participants6 Participants
Race (NIH/OMB)
White
10 Participants7 Participants18 Participants35 Participants
Region of Enrollment
United States
11 participants10 participants28 participants49 participants
Sex: Female, Male
Female
1 Participants1 Participants11 Participants13 Participants
Sex: Female, Male
Male
10 Participants9 Participants17 Participants36 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 210 / 210 / 37
other
Total, other adverse events
3 / 212 / 210 / 37
serious
Total, serious adverse events
0 / 210 / 210 / 37

Outcome results

Primary

Postconcussive Sensory Symptoms

The NSI is a validated scale of postconcussive symptoms; the Somatic Subscale score captures severity of physical symptoms such as tinnitus, blurry vision, loss of balance, and insomnia. (range 0-48; 0-12 mild; 13-24 moderate; 25-36 severe; 37-48 very severe)

Time frame: 2 week visit

Population: For active and sham, analysis population includes all participants who completed intervention and all pre-intervention and post-intervention visit assessments. For imaging only group, analysis includes all participants who completed all pre-intervention visit assessments.

ArmMeasureGroupValue (MEAN)Dispersion
Active StimulationPostconcussive Sensory SymptomsPre-Intervention (baseline visit)19.9 score on a scaleStandard Deviation 10.5
Active StimulationPostconcussive Sensory SymptomsPost-Intervention (2 week visit)20.6 score on a scaleStandard Deviation 9.4
Sham StimulationPostconcussive Sensory SymptomsPre-Intervention (baseline visit)18.9 score on a scaleStandard Deviation 11.3
Sham StimulationPostconcussive Sensory SymptomsPost-Intervention (2 week visit)17.5 score on a scaleStandard Deviation 9.5
Imaging OnlyPostconcussive Sensory SymptomsPre-Intervention (baseline visit)2.9 score on a scaleStandard Deviation 3.3
Secondary

Magnetoencephalography Peak Activation

Peak activation during the Auditory Orienting Task (AOT) performed during magnetoencephalography

Time frame: 2 week visit

Population: For active and sham intervention groups, analysis population includes all participants who completed intervention

ArmMeasureGroupValue (MEAN)Dispersion
Active StimulationMagnetoencephalography Peak ActivationPre-Intervention (baseline visit)3.07 femtoteslaStandard Deviation 0.87
Active StimulationMagnetoencephalography Peak ActivationPost-Intervention (2 week visit)3.68 femtoteslaStandard Deviation 1.42
Sham StimulationMagnetoencephalography Peak ActivationPre-Intervention (baseline visit)3.49 femtoteslaStandard Deviation 0.92
Sham StimulationMagnetoencephalography Peak ActivationPost-Intervention (2 week visit)3.46 femtoteslaStandard Deviation 1.03
Imaging OnlyMagnetoencephalography Peak ActivationPre-Intervention (baseline visit)3.31 femtoteslaStandard Deviation 0.9

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026